China Human Vaccine Industry (Hepatitis B, Influenza, Rabies & Pneumonia) 2017 Forecasts - KNOE 8 News; KNOE-TV; KNOE.com |

China Human Vaccine Industry (Hepatitis B, Influenza, Rabies & Pneumonia) 2017 Forecasts

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Life Science Industry Research

DALLAS, August 31, 2014 /PRNewswire/ --

LifeScienceIndustryResearch.com adds "China Human Vaccine Industry Report, 2014-2017" that says vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China's human vaccine lot release volume grew by 4.9% from a year earlier, and the market size expanded 2.8% year on year. As vaccination is suspected of causing death and some companies (such as Shenzhen Kangtai, Tiantan Biological and Dalian Hissen) have to shut down the production of some products after failing to pass the new GMP certification, China's human vaccine market supply and demand may witness a slight decline in 2014, but it is still expected to grow steadily in the long run.

Affected by China's economic level, national vaccine prevention policies and people's awareness, free EPI vaccines prevail in China with a share of approximately 80% in the total lot release volume. Also, the Chinese health authorities are trying to improve the quality of EPI vaccines. For example, Huizhou City of Guangdong province takes the lead to contain poliomyelitis inactivated vaccines into its immunization program (Sanofi Pasteur acts as a supplier in this program) for a trial in 2014. However, this program stipulates the injection of the poliomyelitis inactivated vaccine "IPV" for the first two vaccinations, while requires the oral administration of the poliomyelitis attenuated vaccine "OPV" for the third and fourth vaccinations.

Chinese human vaccine market is still dominated by Beijing Tiantan Biological, Chengdu Institute of Biology under Chinese Academy of Sciences, Shanghai Institute of Biological Products Co., Ltd. , Lanzhou Institute of Biological Products Co., Ltd., Wuhan Institute of Biological Products Co., Ltd., Changchun Institute of Biological Products Co., Ltd., Institute of Medical Biology under Chinese Academy of Medical Sciences and other state-owned enterprises; but, their market share is falling. In 2013, the lot release volume of Chinese state-owned enterprises accounted for 69.9%, down 8.6 percentage points compared with last year; whereas, the share of private and foreign-funded enterprises jumped by 6 percentage points and 2.6 percentage points over the previous year respectively.

Order a copy of this report at http://www.lifescienceindustryresearch.com/purchase?rname=21800 .

The improved quality of Chinese vaccines, the increased export tax rebates (from 13% in 2009 to 15%) and other favorable factors have prompted China's human vaccine export volume and value to grow quickly. From January to June of 2014, the export volume and value amounted to 65.08 tons and USD15.45 million respectively, representing the separate increase of 115.6% and 50% over the same period of last year.

As China's vaccine regulatory system is recognized by WHO, Chengdu Institute of Biology under Chinese Academy of Sciences, Beijing Tiantan Biological, Hualan Biological and other domestic vaccine companies are actively submitting pre-certification application to WHO in order to further expand overseas markets. In October 2013, the JE (Japanese encephalitis) vaccines of Chengdu Institute of Biology under Chinese Academy of Sciences were pre-certified by WHO at first and included in the procurement list of the United Nations. WHO inspected the influenza (split virion) vaccines of Hualan Biological on the spot in April 2014, and these vaccines are expected to be exported in 2015.

Comprehensive Table of Contents and more for the report "China Human Vaccine Industry Report, 2014-2017" is available at http://www.lifescienceindustryresearch.com/china-human-vaccine-industry-report-2014-2017.html#tabs-2 .

The report covers: Operating environment, status quo and sales channels of China human vaccine industry; Market supply & demand, competition patterns, import & export and development prediction of China human vaccine industry; Market supply & demand, competition patterns and market prices of 10 kinds of vaccine products including hepatitis B vaccine, influenza vaccine, rabies vaccine and pneumonia vaccine in China; Operation, vaccine business and development prospects of 11 Chinese human vaccine enterprises.

Few Points from Table of Contents of China Human Vaccine Industry Report, 2014-2017 : 

5. Major Vaccine Manufacturers in China

5.1 China National Biotec Group

5.2 Hualan Biological Engineering Inc.

5.3 Chongqing Zhifei Biological Products Co., Ltd

5.4 Walvax Biotechnology Co., Ltd

5.5 Sinovac Biotech Ltd.

5.6 Liaoning Chengda Co., Ltd.

5.7 Changchun BCHT Biotechnology Co. Ltd.

5.8 Changchun Changsheng Life Sciences Limited

5.9 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd

5.10 Shenzhen Kangtai Biological Products Co. Ltd

5.11 Dalian Hissen Bio-Pharm Co., Ltd

List of Figures

Classification of Vaccines

Vaccine Industry Chain

EPI Human Vaccine Varieties in China, 2013

Global Human Vaccine Market Scale, 2008-2013

Sales Value of the Global Top 5 Human Vaccine Manufacturers, 2008-2013

Top 10 Best-selling Vaccines Worldwide, 2013

Main Mergers & Acquisitions in the Vaccine Industry Worldwide, 2005- 2014

Policies in Vaccine Industry in China

Operating Revenue and Total Profit of Biological & Biochemical Product Industry in China, 2007- 2014

China's Human Vaccine Market Scale, 2007-2013

Major Human Vaccine Varieties and Producers in China

Gross Margin of Major Human Vaccine Manufacturers in China, 2007-2013

The Release and Percentage (by Volume) of EPI and Extra EPI Vaccines in China, 2007-2013

China's EPI Human Vaccine Market Shares by Release, 2008-2013

China's Extra EPI Human Vaccine Market Shares by Release, 2008-2013

Vaccine Business Revenue of Key Vaccine Enterprises in China, 2011-2013

Development of Some New Vaccine in China by the end of Aug., 2014

Some Events Related to Vaccine Business of Foreign Enterprises in China, 2011-2013

Vaccine Distribution Channel in China

Lot Release Volume of Hepatitis B Vaccine in China by Dosage Form, 2007-2013

Hepatitis B Vaccine (CHO Cell) Suppliers and Lot Release Volume in China, 2008-2013

Hepatitis B Vaccine (Yeast) Suppliers and Lot Release Volume in China, 2007-2013

Explore more reports on the pharmaceuticals industry at http://www.lifescienceindustryresearch.com/category/pharmaceuticals .

About Us: 

Life Science Industry Research is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, biotechnology, diagnostics, healthcare as well as medical devices and pharmaceuticals. We provide 24/7 online and offline support to our customers.

Priyank Tiwari / Ritesh Tiwari, +1-888-391-5441

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and KNOE. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.